Cellectis S.A. (NASDAQ:CLLS) Given Consensus Rating of “Moderate Buy” by Analysts

Cellectis S.A. (NASDAQ:CLLS) has received an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $7.00.

A number of research firms recently weighed in on CLLS. Citizens Jmp reissued a “market outperform” rating and issued a $8.00 target price on shares of Cellectis in a report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research report on Monday, April 20th. Finally, Barclays assumed coverage on shares of Cellectis in a research note on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price objective for the company.

Cellectis Stock Performance

NASDAQ CLLS opened at $2.67 on Friday. The stock has a market capitalization of $267.91 million, a PE ratio of -3.99 and a beta of 2.88. The business has a 50 day simple moving average of $3.26 and a two-hundred day simple moving average of $3.66. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.52 and a quick ratio of 1.52. Cellectis has a 1-year low of $1.77 and a 1-year high of $5.48.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.08. The business had revenue of $7.55 million for the quarter, compared to analysts’ expectations of $11.04 million. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.

Institutional Investors Weigh In On Cellectis

Several institutional investors have recently modified their holdings of the stock. Lido Advisors LLC purchased a new position in shares of Cellectis in the 1st quarter worth approximately $32,000. Marshall Wace LLP lifted its position in Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock worth $864,000 after buying an additional 168,038 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Cellectis during the fourth quarter worth $15,385,000. Global Retirement Partners LLC bought a new position in Cellectis during the fourth quarter valued at $34,000. Finally, Millennium Management LLC increased its position in Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 22,080 shares during the last quarter. 63.90% of the stock is owned by institutional investors.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.